Calcium Channel Blockers: Dihydropyridines and Non-Dihydropyridines in Hypertension and Angina

Core concept: L-type calcium channels and “where” the drug acts

Calcium channel blockers (CCBs) used in cardiovascular care primarily inhibit L-type calcium channels. These channels are important in two places:

• Vascular smooth muscle: calcium entry promotes contraction; blocking it causes arteriolar vasodilation → lower systemic vascular resistance (afterload) and lower blood pressure.
• Cardiac tissue (SA/AV node and myocardium): calcium entry supports pacemaker activity and conduction; blocking it can slow heart rate and slow AV nodal conduction (and reduce contractility to varying degrees).

The clinical effects depend on the subtype: dihydropyridines (DHPs) are more vascular, while non-dihydropyridines (non-DHPs) are more cardiac.

1) Subtypes: Dihydropyridines vs non-dihydropyridines

Dihydropyridines (vascular-selective)

Common examples: amlodipine, nifedipine (extended-release), felodipine, nicardipine, clevidipine.

• Main action: arteriolar vasodilation → ↓ afterload → ↓ BP.
• Heart rate effect: may cause reflex tachycardia (especially shorter-acting agents or rapid dose escalation) because vasodilation triggers sympathetic activation.
• Best fit: hypertension and angina when you want afterload reduction without intentionally slowing AV conduction.

Non-dihydropyridines (cardiac-selective)

Common examples: verapamil, diltiazem.

• Main action: ↓ SA node automaticity and ↓ AV nodal conduction; also some vasodilation.
• Heart rate effect: bradycardia and AV block risk; negative inotropy can worsen certain heart failure states.
• Best fit: angina when heart rate reduction is desired; rate control for certain supraventricular tachyarrhythmias.

2) Hypertension: when a CCB is chosen (practical approach)

CCBs are commonly used for blood pressure control because they reliably reduce afterload via arteriolar dilation. In routine outpatient hypertension management, DHP CCBs are often the default CCB choice because they lower BP without intentionally slowing cardiac conduction.

Continue in our app.

• Listen to the audio with the screen off.
• Earn a certificate upon completion.
• Over 5000 courses for you to explore!

Or continue reading below...

Download the app

Step-by-step: choosing and starting a CCB for hypertension

1. Clarify the goal: Is the main problem elevated BP, or is there also a need to slow heart rate (e.g., tachyarrhythmia)? If it’s primarily BP, think DHP.
2. Select the subtype:
   • DHP (e.g., amlodipine) when you want strong BP lowering and minimal conduction effects.
   • Non-DHP only if there is a compelling need for rate control and the patient has no significant conduction disease and no high risk of worsening heart failure.
3. Start low and titrate: gradual titration reduces symptomatic hypotension and reflex tachycardia (more relevant with faster-onset agents).
4. Plan monitoring: check BP response, ask about ankle swelling, and review heart rate (especially with non-DHPs).
5. Anticipate common tolerability issues: if edema develops, confirm it is medication-related (often bilateral, worse at end of day) and consider dose reduction or regimen adjustment rather than automatically adding a diuretic.

Common clinical scenarios

• Hypertension with baseline bradycardia or conduction disease: prefer a DHP; avoid non-DHPs due to bradycardia/AV block risk.
• Hypertension with bothersome tachycardia: a non-DHP may help if appropriate, but weigh heart failure risk and drug interactions; many patients will instead use other rate-controlling strategies depending on the broader regimen.
• Need for potent BP lowering without affecting electrolytes: DHPs are useful because they do not typically cause clinically significant electrolyte disturbances.

3) Angina management: afterload reduction and myocardial oxygen demand

Angina occurs when myocardial oxygen demand exceeds supply. CCBs help by lowering demand and, in some cases, improving supply.

How CCBs help angina

• DHPs: arteriolar vasodilation → ↓ afterload → the heart pumps against less resistance → ↓ myocardial oxygen demand. Some agents also dilate coronary arteries, which may help oxygen supply.
• Non-DHPs: provide afterload reduction plus ↓ heart rate and ↓ contractility → strong reduction in oxygen demand (rate reduction is particularly helpful when angina is triggered by exertion).

Practical selection for angina symptoms

1. Identify the dominant trigger:
   • If angina is associated with high BP and normal/high heart rate, a DHP can reduce afterload.
   • If angina is associated with elevated heart rate or you want direct rate slowing, consider a non-DHP (if no contraindications).
2. Watch for reflex tachycardia with DHPs: reflex tachycardia can increase oxygen demand and potentially worsen angina in susceptible patients, especially with rapid-onset/short-acting formulations. Prefer longer-acting options and cautious titration.
3. Assess heart failure risk: avoid non-DHPs in patients with reduced systolic function or decompensated heart failure due to negative inotropy and conduction slowing.

4) Rate control role (non-DHPs) in certain tachyarrhythmias

Non-DHP CCBs (verapamil and diltiazem) slow conduction through the AV node. This makes them useful for ventricular rate control in certain supraventricular tachyarrhythmias where the AV node is part of the pathway or is the “gatekeeper” to the ventricles.

Step-by-step: using a non-DHP for rate control (conceptual workflow)

1. Confirm the rhythm type and stability: rate-control therapy is typically for stable supraventricular rhythms (e.g., atrial fibrillation/flutter rate control, some SVTs). Unstable patients require urgent management per protocol.
2. Screen for contraindications:
   • Baseline bradycardia, second- or third-degree AV block (unless paced), or significant conduction disease.
   • Worsening heart failure risk (especially reduced ejection fraction or decompensation).
3. Review interacting medications: avoid stacking AV nodal blockers without a clear plan (see interactions below).
4. Monitor response: check heart rate, symptoms (dizziness, syncope), and consider ECG if conduction issues are suspected.

Safety and adverse effects (what to expect and what to act on)

Class-wide and common (especially DHPs)

• Peripheral edema: due to preferential arteriolar dilation increasing capillary hydrostatic pressure; often ankle/lower-leg swelling.
• Flushing and headache: from vasodilation.
• Gingival hyperplasia: counsel on oral hygiene and dental follow-up.

Non-DHP–specific concerns

• Constipation: particularly with verapamil; ask proactively and manage with hydration, fiber, and bowel regimen if needed.
• Bradycardia and AV block: due to AV nodal suppression; risk increases with higher doses, older age, and interacting drugs.
• Worsening heart failure: negative inotropy can reduce cardiac output in susceptible patients.

Reflex tachycardia considerations (primarily DHPs)

Rapid vasodilation can trigger sympathetic activation → tachycardia and palpitations. This is less prominent with longer-acting agents (e.g., amlodipine) and careful titration. Reflex tachycardia matters because it can increase myocardial oxygen demand and may aggravate angina in some patients.

Drug interactions and counseling points

CYP3A4 interactions (many CCBs)

Many CCBs are metabolized by CYP3A4. This means:

• CYP3A4 inhibitors can increase CCB levels → more hypotension, edema, bradycardia (non-DHPs), dizziness.
• CYP3A4 inducers can decrease CCB levels → reduced BP or rate-control effect.

Practical step: when a new medication is added (including some antibiotics/antifungals or seizure medications), reassess BP/HR and side effects within days to weeks depending on the change.

Additive bradycardia with beta-blockers (non-DHPs)

Non-DHPs + beta-blockers can produce excessive AV nodal blockade → marked bradycardia, hypotension, or heart block. If combination therapy is considered, it should be done with a clear indication and close monitoring (often with ECG assessment depending on patient risk).

Grapefruit juice counseling

Grapefruit juice can inhibit intestinal CYP3A4 and increase levels of certain CCBs. Counseling script: Avoid grapefruit and grapefruit juice while taking this medication unless your prescriber confirms it is safe for your specific CCB and dose.

Monitoring: what to check and when

Routine monitoring for all CCBs

• Blood pressure: home BP logs are useful; watch for symptomatic hypotension (lightheadedness, falls).
• Edema: ask about ankle swelling, shoe tightness, and end-of-day worsening; examine for bilateral pitting edema.
• Adverse vasodilatory symptoms: headache, flushing, dizziness.

Additional monitoring for non-DHPs

• Heart rate: resting HR and symptom review (fatigue, presyncope, syncope).
• ECG considerations: obtain or review ECG if there are symptoms of conduction slowing, if the patient has known conduction disease, or if combining with other AV nodal–blocking agents; watch PR interval prolongation and AV block patterns.
• Heart failure status: monitor for weight gain, dyspnea, edema worsening, and reduced exercise tolerance; reassess appropriateness if symptoms suggest decompensation.